Abstract
The novel imidazoisoquinoline SDZ 62-434, originally identified as a platelet-activating factor (PAF) antagonist, has antiproliferative activity in a range of cell lines from human solid and haematological malignancies. Using an MTT cytotoxicity assay, IC50 values of 5 microM - 111 microM were observed following a 24 h exposure. Similar results were obtained using a clonogenic assay. The HT29 colon adenocarcinoma was particularly sensitive while the MCF-7 breast carcinoma was the most resistant in our panel. Only a 2-3 fold cross-resistance was seen in the doxorubicin and cisplatin resistant variants of the A2780 ovarian carcinoma; the drug did not modulate sensitivity to doxorubicin in either parent or resistant lines. No cross-resistance to SDZ 62-434 was seen in a doxorubicin-resistant MCF-7 variant. Cytotoxicity was not due to non-specific membrane lysis. The potent PAF antagonist WEB 2086 did not modulate SDZ 62-434 cytotoxicity, indicating no role for PAF receptors. Precursor incorporation studies in A2780 cells showed that DNA synthesis was inhibited more effectively than protein synthesis while RNA synthesis was unaffected. SDZ 62-434 inhibited both bombesin and platelet-derived growth factor-induced DNA synthesis in quiescent Swiss 3T3 cells. This suggests a possible role for SDZ 62-434 as an inhibitor of signal transduction in cancer cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brunton, V., Workman, P. In vitro antitumour activity of the novel imidazoisoquinoline SDZ 62-434. Br J Cancer 67, 989–995 (1993). https://doi.org/10.1038/bjc.1993.181
Issue Date:
DOI: https://doi.org/10.1038/bjc.1993.181
This article is cited by
-
Novel modulatory effects of SDZ 62-434 on inflammatory events in activated macrophage-like and monocytic cells
Naunyn-Schmiedeberg's Archives of Pharmacology (2008)
-
Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086
British Journal of Cancer (2006)
-
Structure-activity relationship studies of isoquinolinone type anticancer agent
Archives of Pharmacal Research (2001)
-
Studies on the synthesis andin vitro antitumor activity of the isoquinolone derivatives
Archives of Pharmacal Research (1999)
-
Synthesis and structure-activity relationship studies of substituted isoquinoline analogs as antitumor agent
Archives of Pharmacal Research (1998)